Medical and Biotech

• Your science is genuinely differentiated but the content that represents it is not: The clinical evidence, the mechanism of action, the manufacturing precision, and the patient outcomes that distinguish your product from every competing approach are invisible in a data sheet and a peer-reviewed abstract. The content that should make those differentiators visible to clinicians, procurement committees, and investors — clinical education video, product demonstration, mechanism of action animation — either does not exist, was produced once and is now outdated, or does not meet the production standard the audience expects from an organisation claiming to operate at the level you claim.‍
• Clinical and commercial communications operate on separate tracks with no shared infrastructure: The medical affairs team is producing KOL content. The commercial team is producing sales enablement video. The marketing team is producing brand content. The investor relations team is producing programme updates. Each track has its own vendor, its own brief, its own visual standard, and its own approval process — producing a library of content that does not cohere into a unified organisational communications strategy and does not compound in the way a systematic program would.‍
• Regulatory and compliance review creates unpredictable production timelines: Every piece of external content requires medical, legal, and regulatory review before it can be published. Most production workflows were not built with the compliance review process integrated from the start — which means compliance review is retrofitted at the end of the production process, creating the bottlenecks, the revision cycles, and the timeline failures that make video production feel more expensive and more painful than it should be.‍
• Investor communications are produced reactively and the quality reflects it: Program milestone announcements, data readout communications, conference presentations, and investor day content are produced individually — each one a separate coordination effort under deadline pressure, with no documented production standard, no consistent visual treatment, and no content library to draw from. The communications that should be building investor confidence and analyst credibility are instead demonstrating the absence of a systematic communications infrastructure.‍
• Clinical education content is not keeping pace with the clinical evidence: The clinical evidence base for your product is growing — new data, new indications, new patient populations, new real-world outcomes. The clinical education content that should communicate that evidence to the prescribing clinicians and procurement committees who need it is not keeping pace — because there is no documented workflow for translating new evidence into new educational video content on a consistent timeline.‍
• The mechanism of action is the most compelling thing about the product and most audiences cannot visualize it: The molecular interaction, the cellular mechanism, the device function, or the biological pathway that makes your product work — and that makes it genuinely different from every existing approach — cannot be filmed. It can be animated. And for most medical and biotech products, the animation that makes the mechanism visible to a clinician, an investor, or a patient is the single highest-value video asset the organisation can produce. Most organisations produce it once, in a format that quickly becomes outdated, without a documented process for keeping it current.

Medical and biotech companies need video that makes complex science easier to understand and trust.

Medical and biotech companies communicate with some of the most demanding audiences in any industry.

Clinicians, investors, regulators, patients, partners, and payers all need different levels of scientific detail, but they share the same requirement: the information must be clear, credible, and accurate.

That is where consistent medical and biotech video production creates leverage.

Video can make complex mechanisms visible, bring clinical expertise forward, and connect scientific progress to real patient outcomes.

A mechanism-of-action animation can show how a therapy or technology works at a level that is difficult to communicate through text alone. A KOL or investigator video can add clinical context around evidence, patient selection, and real-world application. A patient story can show the human impact behind the data in a way that makes outcomes easier to understand and remember.

VID helps medical and biotech companies produce:

• Mechanism-of-action animation
• Clinical education video
• KOL and investigator interviews
• Product and device demonstrations
• Patient stories
• Scientific platform explainers
• Investor communications
• Sales enablement
• Training and LMS content
• Regulatory and stakeholder communications

Through VID Operate, these assets are produced through an ongoing system rather than as isolated projects.

The result is a growing video library that helps different audiences understand the same science at the right level of depth—without sacrificing accuracy, rigor, or brand consistency.

VID's medical and biotech clients share a specific profile. They are established organisations — commercial-stage medical device companies, clinical-stage biotech firms, healthcare technology platforms, and diagnostic companies — with genuine scientific or clinical differentiation and a communications challenge that their current content operation is not fully solving.

You are the right fit if:

• You are a commercial-stage or late clinical-stage medical device, pharmaceutical, or biotech company whose clinical and commercial communications need to communicate complex science clearly and compliantly to multiple audiences simultaneously
• You are a healthcare technology company — digital health platform, clinical decision support, remote patient monitoring — whose product requires video demonstration and whose current product content does not match the sophistication of the technology it represents
• You are a diagnostic company — molecular diagnostics, imaging, point-of-care — whose clinical utility needs to be communicated to ordering clinicians, procurement committees, and laboratory directors in a format that static sales materials cannot achieve
• You are a life sciences company preparing for a major inflection point — a pivotal data readout, a regulatory submission, a commercial launch, or an investor day — whose communications infrastructure needs to be ready before the moment rather than assembled in its aftermath
• You are a biotech or medical device company whose mechanism of action animation is outdated, whose clinical education content is not keeping pace with the evidence, or whose investor communications are produced reactively rather than systematically
• You are a commercial medical device or pharmaceutical company whose sales enablement content is not consistently reaching every rep in every territory at the standard the product and the evidence require